MLST nucleotide sequences for the eleven clinical isolates determined in this study have been deposited in the GenBank nucleotide sequence database under accession numbers MK344035-MK344111.

Introduction {#sec001}
============

*Cryptococcus* is a life-threatening fungal pathogen of humans and animals\[[@pntd.0008493.ref001]\]. The infection process of *Cryptococcus* is usually via the inhalation of airborne spores (or yeast cells) into the respiratory tract and their subsequent dissemination to the central nervous system, causing pulmonary cryptococcosis and cryptococcal meningoencephalitis\[[@pntd.0008493.ref001], [@pntd.0008493.ref002]\]. During the past two decades, considerable genetic heterogeneity has been demonstrated to occur in the *C*. *neoformans*/*gattii* species complexes by a plethora of molecular methods. Various molecular biological techniques have been used to study the epidemiology and population structure of the *Cryptococcus gattii*/*neoformans* species complexes, including random amplification of polymorphic DNA (RAPD) analysis, PCR fingerprinting, amplified fragment length polymorphism (AFLP) analysis, multilocus microsatellite typing (MLMT) analysis and multi-locus sequence typing (MLST) analysis\[[@pntd.0008493.ref003]\]. Recently, next-generation sequencing (NGS) technology has been utilized to investigate the epidemiology of *C*. *gattii* isolates\[[@pntd.0008493.ref004]\]. However, the identification of the species is commonly based on the MLST protocol standardized by the International Society for Human and Animal Mycology (ISHAM)\[[@pntd.0008493.ref005]\]. The MLST scheme has become an important tool for the characterization of the population genetic structure of the *Cryptococcus* species. Since the taxonomy of the polyphyletic genus *Cryptococcus* has been thoroughly revised, two varieties of *C*. *neoformans* have been recognized as species: *C*. *neoformans* (formerly *C*. *neoformans* variety *grubii*) and *C*. *deneoformans* (formerly *C*. *neoformans* variety *neoformans*)\[[@pntd.0008493.ref006]--[@pntd.0008493.ref008]\]. However, the molecular types of *C*. *gattii* species complex have been elevated to the species level as *C*. *gattii sensu stricto* (AFLP4/VGI), *C*. *deuterogattii* (AFLP6/VGII), *C*. *bacillisporus* (AFLP5/VGIII), *C*. *tetragattii* (AFLP7/VGIV) and *C*. *decagattii* (AFLP10/VGIV)\[[@pntd.0008493.ref007]\]. The *C*. *deuterogattii* subtype (AFLP6A/VGIIa, AFLP6B/VGIIb and AFLP6C/VGIIc) caused an outbreak in the Pacific Northwest (PNW) region of Canada and the United States\[[@pntd.0008493.ref009], [@pntd.0008493.ref010]\].

Cryptococcosis is a global and invasive systematic mycosis caused by *C*. *gattii*/*neoformans* species complexes, leading to morbidity and mortality in both immunocompetent and immunocompromised individuals, such as those with acquired immune deficiency syndrome (AIDS) or those undergoing organ transplantation\[[@pntd.0008493.ref011]\]. Infections due to *C*. *neoformans* species complex occur worldwide while cryptococcosis caused by *C*. *gattii* species complex was traditionally considered an endemic disease, and associated with tropical and subtropical climates\[[@pntd.0008493.ref011]\]. However, the outbreaks of *C*. *deuterogattii* in humans and a wide range of mammals in Vancouver Island and the PNW of the USA demonstrates that the fungus has adapted to environments beyond the endemic (sub)tropical regions\[[@pntd.0008493.ref009], [@pntd.0008493.ref010]\]. The source of infection is usually traced back to *Eucalyptus* and other species of trees, such as *Ficus* spp. and *Terminalia* spp. (almond) trees\[[@pntd.0008493.ref012], [@pntd.0008493.ref013]\].

In Asia, the first case of *C*. *gattii* species complex infection was reported by Wanqing Liao in 1980 by the strain formerly named as S~8012~ and now identified as *C*. *gattii s*.*s*.\[[@pntd.0008493.ref014]\]. *C*. *gattii s*.*s*. is the most frequently encountered species worldwide\[[@pntd.0008493.ref003]\], and only a few sporadic cases of *C*. *deuterogattii* infection have been reported in Asian countries such as India, Thailand, and Malaysia\[[@pntd.0008493.ref015]\]. In 2007, Okamoto *et al*. reported the first case of cryptococcosis caused by a highly virulent *C*. *deuterogattii* subgenotype (AFLP6A/VGIIa) in Japan\[[@pntd.0008493.ref016]\]. However, to our knowledge, reports of *C*. *gattii* species complex infection in China are limited. A study in 2008 showed that nine of 115 (7.8%) clinical *Cryptococcus* isolates were members of the *C*. *gattii* species complex, consisting of eight strains of *C*. *gattii s*.*s*. and one strain of *C*. *deuterogattii*\[[@pntd.0008493.ref017]\]. Several sporadic *C*. *deuterogattii* infections have also been reported in mainland China, mainly in southern China\[[@pntd.0008493.ref018], [@pntd.0008493.ref019]\]. However, the genetic identity and variability of these isolates and the phylogenetic relationships among these clinical isolates and global isolates have yet to be thoroughly investigated.

In this study, we described eleven cases of cryptococcosis caused by *C*. *gattii* species complex infections between 2014 and 2018 in Guangxi, southern China. We determined their genotypes by MLST and studied their phylogenetic relationships with the global strains. We also characterized the mating type, physiological characteristics, virulence factors and antifungal susceptibility of these clinical isolates.

Materials and methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

This study was approved by the Medical Ethics Committee of First Affiliated Hospital of Guangxi Medical University. All participants were adults. The clinical data in this study was obtained with the written consent of the patient or the patient's family and data collected concerning them was anonymized.

Selection of *C*. *gattii* species complex from clinical isolates {#sec004}
-----------------------------------------------------------------

To study the epidemiological characteristics of cryptococcosis caused by *C*. *gattii* species complex in Guangxi, southern China, all the clinical strains of *Cryptococcus* spp. stored in the Fungal Diseases Survey Center of Guangxi, the First Affiliated Hospital of Guangxi Medical University Guangxi, southern China, have been evaluated. In total, one hundred and twenty *Cryptococcus* strains were isolated from patients with clinically confirmed cryptococcosis between 2014 and 2018. All but three were isolated from the patients hospitalized in First Affiliated Hospital of Guangxi Medical University, which is the largest tertiary care hospital in the Guangxi Autonomous Region in southern China and has 2750 beds. Two strains were from The Fourth People\'s Hospital of Nanning and one strain was from the People\'s Hospital of Guangxi Zhuang Autonomous Region. Among the 120 strains, most of them were from incident patients, except one (GX0049) was a relapse patient. Six strains isolated from the bronchoalveolar lavage fluid (BALF), three from lung tissue and two from skin tissue; the other strains isolated from CSF. The data of the patients was collected using a standardized form that was based entirely on the medical reports of each patient, including demographic information (age and gender), domiciles, birth and development details, medical history, clinical manifestations, laboratory data, imaging changes, diagnoses, treatments, and prognoses.

All strains were subcultured on Sabouraud Dextrose Agar (SDA) plates and incubated at 25°C, and then transferred onto L-Canavanine-glycine-bromothymol blue (CGB) medium for three to seven days to differentiate *C*. *neoformans* from *C*. *gattii* species complex as previously described \[[@pntd.0008493.ref020]\]. In the CGB medium, eleven isolates had a positive reaction and turned the medium blue, while the rest of isolates failed to produce a color change, which were further identified as *C*. *neoformans* var. *grubii* by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Among the eleven strains of *C*. *gattii* species complex, ten strains were isolated from CSF, and one strain was isolated from lung tissue.

Reference *Cryptococcus* strains R265 (AFLP6A/VGIIa) and H99 (AFLP1/VNI) were acquired from Shanghai Key Laboratory of Molecular Medical Mycology, Changzheng Hospital, Second Military Medical University, Shanghai, China. *MAT*a strains (AFLP2/VNIV, AFLP1/VNI and AFLP6/VGII) were obtained from State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

MLST and phylogenetic analysis {#sec005}
------------------------------

Isolates were cultured on SDA for 72 h prior to DNA extraction. Genomic DNA was extracted with the NuClean Plant Genomic DNA Kit (CWBIO, Beijing, China). Based on the ISHAM consensus MLST scheme, seven loci including capsule polysaccharide (*CAP59*), glycerol 3-phosphate dehydrogenase, (*GPD1*), laccase (*LAC1*), the intergenic spacer (*IGS1*) region, phospholipase B1 (*PLB1*), superoxide dismutase (*SOD1*), and orotidine monophosphate pyrophosphorylase (*URA5*) genes were amplified and sequenced\[[@pntd.0008493.ref005]\]. The alleles were analyzed, and the STs were determined based on the MLST database ([http://mlst.mycologylab.org](http://mlst.mycologylab.org/)). The sequences of the seven MLST loci have been deposited in the MLST database and GenBank.

Phylogenetic analysis of the *C*. *gattii* species complex was performed based on the alignment of seven concatenated nucleotide sequences (*CAP59*, *GPD1*, *LAC1*, *IGS1*, *PLB1*, *SOD1* and *URA5*)\[[@pntd.0008493.ref021]\]. The genetic relationships among these Chinese clinical strains and strains in different countries\[[@pntd.0008493.ref021]--[@pntd.0008493.ref023]\] were investigated by MEGA7\[[@pntd.0008493.ref024]\]; a phylogenetic tree was generated using the maximum likelihood method with a bootstrap analysis using 1000 replicates\[[@pntd.0008493.ref024]--[@pntd.0008493.ref026]\]. Principal component analysis (PCA) was performed with the Adegenet 2.1.1 package for software R (version 3.4.4) to explore the genetic relationships and geographic patterns of the strains\[[@pntd.0008493.ref027]\].

Mating type determination and physiological analysis {#sec006}
----------------------------------------------------

Mating types were determined by using specific primers targeting the *MF*α and *MF*a pheromone genes as previously described\[[@pntd.0008493.ref028]\]. Mating experiments were performed by pairing eleven clinical strains and two reference strains (*MAT*α; AFLP6A/VGIIa R265 and AFLP1/VNI H99) with three strains of the opposite mating type (*MAT*a; AFLP2/VNIV, AFLP1/VNI and AFLP6/VGII) on V8 medium at 25°C in darkness for two weeks. The experiment was carried out twice, and the formation of hyphae and sexual structures was observed and investigated under a microscope.

Since certain strains were able to mate *in vitro*, we also studied and compared their virulence factors to the standard reference strain (R265). Melanin production, and capsule formation were evaluated using slightly modified protocols that were published previously\[[@pntd.0008493.ref029]--[@pntd.0008493.ref031]\]. Visual analysis of melanin production was performed on caffeic acid agar; strains were grown on agar plates incubated at 30°C and 37°C for 72 h and observed the appearance of brown yeast colonies. Capsule formation was induced with RPMI-1640 medium for 72 h at 37°C and 5% CO~2~. The capsule size of at least 100 cells was quantified by light microscopy using encapsulated to naked yeast size (cell wall to cell wall diameter) ratios.

Antifungal susceptibility testing {#sec007}
---------------------------------

Antifungal agents fluconazole (FLC), fluorocytosine (5FC), amphotericin B (AMB), itraconazole (ITC), voriconazole (VOR), posaconazole (POS) and isavuconazole (ISA) were used in the susceptibility tests. The broth microdilution method was performed following the CLSI M27-A3 guidelines\[[@pntd.0008493.ref032]\] to assess the antifungal susceptibility of all clinical isolates *in vitro*. The concentration ranges were 0.125--64 μg/mL for FLC, 0.008--4 μg/mL for 5FC, 0.016--8 μg/mL for AMB and 0.002--1 μg/mL for ITC, VOR, POS and ISA. The MIC values were recorded after incubation at 37°C for 72 h. The MIC of AMB was defined as the lowest concentration of drug showing no yeast growth, while the MICs for other antifungal agents were defined as low drug concentrations that caused a prominent reduction in growth (≥50%) compared with the drug-free growth control. Since there was no established breakpoints standard of antifungal drugs for *Cryptococcus*, therefore, epidemiological cutoff values (ECVs) has been offered to determine whether a strain is wild type (*in vitro* susceptible) or non-wild type (*in vitro* resistant). Based on the previous recommendation\[[@pntd.0008493.ref033]--[@pntd.0008493.ref035]\], the ECVs of *C*. *gattii s*.*s*. for FLC were 8 μg/mL; 4 μg/mL for 5FC; 0.5 μg/mL for AMB, ITC, VOR and POS; and 0.25 μg/mL for ISA. The ECVs of *C*. *deuterogattii* were 32 μg/mL for FLC; 16 μg/mL for 5FC; 1 μg/mL for AMB; 0.5 μg/mL for ITC and POS; and 0.25 μg/mL for VOR and ISA\[[@pntd.0008493.ref033]--[@pntd.0008493.ref035]\]. *Candida parapsilosis* ATCC22019 was used for quality control strain.

Statistical analysis {#sec008}
--------------------

Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). The *p* values of the relative capsule size data were calculated using one-way ANOVA statistical analysis. *p* \< 0.05 was considered statistically significant.

Accession numbers {#sec009}
-----------------

MLST nucleotide sequences for the eleven clinical isolates determined in this study have been deposited in the GenBank nucleotide sequence database under accession numbers

MK344035-MK344111.

Results {#sec010}
=======

Clinical characteristics of *C*. *gattii* species complex cases {#sec011}
---------------------------------------------------------------

The clinical manifestations and medical histories of the 11 patients are summarized in [Table 1](#pntd.0008493.t001){ref-type="table"}. A total of ten cryptococcal meningitis (CM) patients and one pulmonary cryptococcosis (PC) patients were enrolled. The population included eight males and three females, with a mean age of 38.0±7.8 years (range 29--54 years). Among ten CM patients, the common clinical manifestation was headache, fever, vomiting and nausea. All of the ten CM patients were positive for CSF ink staining and nine of them were positive for CSF cryptococcal antigen latex agglutination test (titer 1:16--1:1024). Chest pain was the most obvious symptom in the patient with PC (GX0717). Chest CT showed a nodular shadow (0.6 cm in diameter) in the right lower lobe and multiple patchy shadow of the lungs; pathologic examination of the lung tissue biopsy demonstrated the cryptococcal yeast forms. Only one patient (GX0080) was previously diagnosed as systemic lupus erythematosus (SLE) and received corticosteroid treatment. Whereas, no significant immune abnormalities was detected in other patients.

10.1371/journal.pntd.0008493.t001

###### Epidemiological and clinical characteristics of eleven patients with *Cryptococcus gattii* species complex infections in Guangxi, southern China[\*](#t001fn001){ref-type="table-fn"}.

![](pntd.0008493.t001){#pntd.0008493.t001g}

  Case no.   Age,y/ gender   Occupation      Clinical syndrome                                         Physical signs                                          Specimen cultured   Latex agglutination test   Clinical diagnosis   Treatment                          Outcome
  ---------- --------------- --------------- --------------------------------------------------------- ------------------------------------------------------- ------------------- -------------------------- -------------------- ---------------------------------- ----------
  GX0049     37/M            Worker          Convulsion, altered consciousness, limb weakness, fever   Meningeal irritation and pathological reflex positive   CSF                 1:64                       CM                   AMB(1275mg)+FLC(13.2g)+5FC(270g)   Survived
  GX0079     40/M            Truck driver    Headache, vomiting, blurred vision                        Neck stiffness                                          CSF                 1:256                      CM                   Unknown                            Survived
  GX0080     31/F            Farmer          Fever, headache, nausea, vomiting, chills                 Normal                                                  CSF                 1:16                       CM                   AMB(2035mg)+FLC(36.4g)             Survived
  GX0158     54/F            Farmer          Headache, nausea, vomiting, fever                         Normal                                                  CSF                 1:128                      CM                   AMB(2580mg)+FLC(22g)+5FC(299.5g)   Survived
  GX1622     29/M            Farmer          Headache, vomiting, fever, blurred vision                 Normal                                                  CSF                 1:80                       CM                   AMB(740mg)+FLC(8g)                 Survived
  GX0104     30/M            Farmer          Headache, nausea, vomiting, fever                         Normal                                                  CSF                 1:1024                     CM                   AMB(1800mg)+FLC(39.6g)+5FC(52g)    Survived
  GX0105     29/F            Unknown         Headache, fever, dizzy, chills                            Neck stiffness, Kernig's sign positive                  CSF                 1:64                       CM                   AMB(1625mg)+FLC(26.4g)+5FC(248g)   Survived
  GX0147     44/M            Farmer          Headache, fever, chills                                   Neck stiffness                                          CSF                 1:1024                     CM                   AMB(189mg)+FLC(5g)+5FC(30g)        Died
  GX0476     42/M            Unknown         Headache, fever, cough                                    Normal                                                  CSF                 None                       CM                   Unknown                            Survived
  GX0903     36/M            Aquiculture     Headache, dizzy, nausea, vomiting, fever                  Neck stiffness                                          CSF                 1:32                       CM                   AMB(2200mg)+FLC(20.8g)+5FC(278g)   Survived
  GX0717     47/M            Civil servant   Chest pain, cough, expectoration                          Normal                                                  Lung tissue         None                       PC                   AMB(140mg)+FLC(2.4g)               Survived

\*Cerebrospinal fluid, CSF; CM, Cryptococcal meningitis; PC, Pulmonary cryptococcosis

According to Infectious Diseases Society of America (IDSA) guidelines and China\'s expert consensus on the diagnosis and treatment of cryptococcal meningitis\[[@pntd.0008493.ref036], [@pntd.0008493.ref037]\], most of the patients have been significantly relieved after the cryptococcosis induction period treatment with combination therapy of two (AMB and FLC) or three (AMB, FLC and 5FC) antifungal drugs. Median cumulative dose and duration were 1625 mg (range 140--2580 mg) and 47 days (range 5--63 days) for AMB, 259 g (range 30--299.5 g) and 45.5 days (range 5--63 days) for 5FC, 20.8 g (range 2.4--39.6 g) and 50 days (range 6--66 days) for FLC. Even after the infection was treated and discharged from hospital, most patients continued the antifungal treatment with 0.2 g-0.4 g/day of FLC. Despite antifungal treatment, one patient died (GX0147) after giving up treatment because of no significant improvement. No patient had travel history outside China.

Identification of sequence type {#sec012}
-------------------------------

MLST analysis of the eleven isolates indicated that five isolates were *C*. *gattii s*.*s*., and the other six isolates belonged to *C*. *deuterogattii* (Figs [1](#pntd.0008493.g001){ref-type="fig"} and [2](#pntd.0008493.g002){ref-type="fig"}, [Table 2](#pntd.0008493.t002){ref-type="table"}). Five and three different sequence types (STs) were detected in *C*. *gattii s*.*s*. and *C*. *deuterogattii*, respectively; essentially all *C*. *gattii s*.*s*. isolates were genetically different and represented by a single isolate when MLST sequences were analyzed ([Fig 1](#pntd.0008493.g001){ref-type="fig"}); sample GX0079 was quite divergent from the selected AFLP4/VGI strains. In contrast, *C*. *deuterogattii* isolates were divided into three major groups, with ST169 and ST129 represented by more than one isolate ([Table 2](#pntd.0008493.t002){ref-type="table"}).

![Phylogenetic analysis of eleven *C*. *gattii* species complex.\
Phylogenetic relationships inferred from a maximum likelihood analysis of *CAP59*, *GPD1*, *LAC1*, *IGS1*, *PLB1*, *SOD1* and *URA5* sequences of eleven *C*. *gattii* species complex from Guangxi, southern China (in blue) and 18 reference strains, covering the four major molecular types in *C*. *gattii* species complex. The branches with bootstrap support higher than 70% are shown.](pntd.0008493.g001){#pntd.0008493.g001}

![Phylogenetic analysis of *C*. *deuterogattii* isolates.\
The figure showing the relationships between the Chinese (strains of current investigation in red) and global *C*. *deuterogattii* strains inferred from the maximum likelihood analysis based on the combined ISHAM consensus MLST loci using MEGA7. Standard reference strains *C*. *gattii s*.*s*. (WM179), *C*. *bacillisporus* (WM161), *C*. *tetragattii* (WM779) and *C*. *decagattii* (IHEM14941) were used as outgroups. Epidemiologically significant isolates from the Pacific Northwest outbreaks were in blue. The branches with bootstrap support of more than 70% are indicated in bold.](pntd.0008493.g002){#pntd.0008493.g002}

10.1371/journal.pntd.0008493.t002

###### The STs and mating types of clinical *Cryptococcus gattii* species complex isolates in Guangxi, southern China[\*](#t002fn001){ref-type="table-fn"}.

![](pntd.0008493.t002){#pntd.0008493.t002g}

  Strains   Allele type   ST   Molecular type   Mating type                                
  --------- ------------- ---- ---------------- ------------- ---- ----- ---- ----- ------ ---
  GX0049    36            11   13               5             13   36    14   106   VGI    α
  GX0079    49            11   59               13            13   71    24   227   VGI    α
  GX0080    16            5    3                5             5    32    12   51    VGI    α
  GX0158    36            11   83               13            13   47    15   222   VGI    α
  GX1622    53            11   13               13            13   68    15   232   VGI    α
  GX0104    40            35   57               4             1    59    2    129   VGII   α
  GX0105    8             6    25               4             1    16    6    129   VGII   α
  GX0147    40            35   57               4             1    59    2    129   VGII   α
  GX0476    2             35   57               4             1    104   2    309   VGII   α
  GX0903    2             25   26               21            9    8     7    169   VGII   α
  GX0717    2             25   26               21            9    8     7    169   VGII   α

\*ST, sequence type

Genetic analysis of the Chinese and global *C*. *deuterogattii* isolates indicated that four Chinese isolates (GX0104, GX0105, GX0147 and GX0476) clustered closely with the *C*. *deuterogattii* AFLP6/VGII strains from Brazil (LMM293 and ILA3279), while the clinical isolates GX0903 and GX0717 clustered in a group containing *C*. *deuterogattii* AFLP6/VGII strains from Spain (CCA242OLD), Singapore (DF12341), the USA (B8973) and France (IP2003/125) ([Fig 2](#pntd.0008493.g002){ref-type="fig"}). These isolates did not cluster with the highly virulent *C*. *deuterogattii* strains (AFLP6A/VGIIa R265 and AFLP6C/VGIIc A6M-R38) reported in the PNW outbreaks in Canada and the USA, but isolate GX0476 clustered in a group forming a sister relationship with the group harboring AFLP6C/VGIIc (A6M-R38) from Oregon, the USA.

Comparison of Chinese and global isolates {#sec013}
-----------------------------------------

PCA (based on ISHAM-MLST) was also used to assess the genetic relationship between Chinese and global isolates ([S1 Fig](#pntd.0008493.s001){ref-type="supplementary-material"}). Approximately 41.8% of the genetic variation can be explained in *C*. *gattii s*.*s*. (PC1 30.0%, PC2 11.8%) ([S1A Fig](#pntd.0008493.s001){ref-type="supplementary-material"}), and 35% of the variation was explained in *C*. *deuterogattii* (PC1 17.9%, PC2 17.1%) ([S1B Fig](#pntd.0008493.s001){ref-type="supplementary-material"}). The PCA did not group *C*. *gattii* species complex strains according to their origin, which was consistent with the results of the phylogenetic analysis ([S1 Fig](#pntd.0008493.s001){ref-type="supplementary-material"}). Among the *C*. *deuterogattii* isolates, the four *C*. *deuterogattii* isolates appeared to be originated from South America.

Physiological characterization {#sec014}
------------------------------

All of the clinical isolates analyzed were *MAT*α ([Fig 3A](#pntd.0008493.g003){ref-type="fig"}). Based on the crossing experiment with JEC20 (AFLP2/VNIV), three *C*. *deuterogattii* strains (GX0104, GX0105 and GX0147) were able to undergo sexual reproduction *in vitro*, and basidia and basidiospores were formed during sexual reproduction ([Fig 3B](#pntd.0008493.g003){ref-type="fig"}). Two *C*. *deuterogattii* isolates (GX0105 and GX0147) exhibited a weak mating response, with only a few filaments, basidia and basidiospores developed.

![**(A) Simultaneous amplification of all clinical strains and two reference strains using primers targeting the *MAT*α and *MAT*a genes and (B) mating reactions of the isolates showing typical basidia and basidiospores. (A)** Reference strains: R265 (*MAT*α, AFLP6A/VGIIa) and JEC20 (*MAT*a, AFLP2/VNIV). Clinical isolates were all *MAT*α. **(B)** Sexual reproduction cultures including hyphae, basidia and basidiospores, incubated on V8 agar (pH = 5) at 25°C for 2 weeks in the dark.](pntd.0008493.g003){#pntd.0008493.g003}

The tested clinical isolates produced melanin at both 30°C and 37°C, while most strains had greater melanin production at 30°C than at 37°C ([S2A Fig](#pntd.0008493.s002){ref-type="supplementary-material"}). Two *C*. *deuterogattii* strains (GX0104 and GX0903) appeared to have greater melanin production than the reference strain (AFLP6A/VGIIa R265) at 37°C. Moreover, these clinical strains produced capsule of different size *in vitro* ([S2B Fig](#pntd.0008493.s002){ref-type="supplementary-material"}); however, our data revealed no significant difference (*p* \> 0.05) in the capsule size between GX0104 and R265 ([S2C Fig](#pntd.0008493.s002){ref-type="supplementary-material"}).

Antifungal drug susceptibility {#sec015}
------------------------------

As the MICs shown in [Table 3](#pntd.0008493.t003){ref-type="table"}, none of the strains demonstrated resistance to the antifungal drugs. The susceptibility ranges of the five *C*. *gattii s*.*s*. isolates were 1--4 μg/mL for FLC, 0.125--0.5 μg/mL for 5FC, 0.25--0.5 μg/mL for AMB, 0.125--0.25 μg/mL for ITC, 0.0156--0.125 μg/mL for VOR, 0.0156--0.25 μg/mL for POS, and 0.0078--0.125 μg/mL for ISA. For the six *C*. *deuterogattii* isolates, the susceptibility ranges were 1--16 μg/mL for FLC, 0.0625--1 μg/mL for 5FC, 0.25--1 μg/mL for AMB, 0.0625--0.25 μg/mL for ITC, 0.0156--0.125 μg/mL for VOR, 0.0156--0.25 μg/mL for POS, and 0.0078--0.125 μg/mL for ISA. According to the clinical efficacy, combination of two or three drugs in AMB, FLC, and 5FC were effective for treatment. There were no significant differences between the *C*. *gattii s*.*s*. and *C*. *deuterogattii* isolates against these seven antifungal drugs (*p* \> 0.05).

10.1371/journal.pntd.0008493.t003

###### Minimal inhibitory concentrations (MICs) of all the *Cryptococcus gattii* species complex isolates in Guangxi, southern China[\*](#t003fn001){ref-type="table-fn"}.

![](pntd.0008493.t003){#pntd.0008493.t003g}

  Strains          Minimal inhibitory concentration (μg/mL)                                                                      
  ---------------- ------------------------------------------ ---------- --------- -------------- --------------- -------------- ---------------
  GX0049           1                                          0.5        0.25      0.125          0.0313          0.0625         0.0313
  GX0079           2                                          0.125      0.5       0.25           0.0625          0.0625         0.0313
  GX0080           1                                          0.25       0.5       0.25           0.0156          0.0156         0.0078
  GX0158           2                                          0.125      0.25      0.125          0.0313          0.0625         0.0313
  GX1622           4                                          0.5        0.5       0.25           0.125           0.25           0.125
  GX0104           1                                          0.0625     1         0.0625         0.0156          0.0156         0.0078
  GX0105           4                                          0.5        0.5       0.25           0.0625          0.0625         0.0625
  GX0147           4                                          1          0.5       0.25           0.0625          0.0625         0.0625
  GX0476           16                                         0.5        0.5       0.125          0.0625          0.25           0.125
  GX0903           2                                          0.25       0.25      0.25           0.0625          0.125          0.125
  GX0717           4                                          0.5        0.5       0.25           0.125           0.125          0.125
  MIC range        1--16                                      0.125--1   0.25--1   0.0625--0.25   0.0156--0.125   0.0156--0.25   0.0078--0.125
  MIC~50~          2                                          0.25       0.5       0.25           0.0625          0.0625         0.0625
  MIC~90~          4                                          0.5        0.5       0.25           0.125           0.25           0.125
  Geometric mean   2.5733                                     0.2836     0.4695    0.1824         0.0486          0.0709         0.0456

\* FLC, fluconazole; 5FC, fluorocytosine; AMB, amphotericin B; ITC, itraconazole; VOR, voriconazole; POS, posaconazole; ISA, isavuconazole; MIC, minimal inhibitory concentration

Discussion {#sec016}
==========

Our current study showed that *C*. *gattii* species complex infection in Guangxi, southern China were caused by both *C*. *gattii s*.*s*. (AFLP4/VGI) and *C*. *deuterogattii* (AFLP6/VGII), with different MLST genotypes and virulence factor characteristics. Similar pattern has also been reported in other countries such as Canada, Brazil, Australia and the USA\[[@pntd.0008493.ref029]--[@pntd.0008493.ref031]\]. Although *C*. *deuterogattii* in this study was genetically indistinguishable from the outbreak genotypes AFLP6A/VGIIa (R265) and AFLP6C/VGIIc (A6M-R38), they were related to other global *C*. *deuterogattii* isolates isolated from Brazil (LMM293 and ILA3279), Singapore (DF12341) and Spain (CCA242OLD). *C*. *deuterogattii* strains are genetically diverse, and there was great genotypic variability among *C*. *deuterogattii* subtypes (AFLP6A/VGIIa and AFLP6C/VGIIc), particularly those in Brazil\[[@pntd.0008493.ref038]\]. Despite the small sample size in this study, most Chinese clinical strains were genetically diverse, with eight STs reported. The variability could be due to special ecological interactions, adaptations and evolutionary mechanisms. *Cryptococcus* species are able to adapt to different ecological niches and temperatures and they can adapt within the host and environment through microevolution. The *Cryptococcus* genome is also dynamic in its plasticity\[[@pntd.0008493.ref039]\].

In the present study, we found that all isolates harbored the *MAT*α gene at the mating type locus, and three of six *C*. *deuterogattii* strains (GX0104, GX0105 and GX0147) were able to undergo sexual reproduction, thus recombination could be one of the causes for the genetic diversity among the Chinese *C*. *deuterogattii* strains. Moreover, offspring produced by sexual reproduction/recombination may be able to adapt to and colonize new environment\[[@pntd.0008493.ref040], [@pntd.0008493.ref041]\]. In the mating assays of eleven clinical strains with the opposite mating type strains (AFLP6/VGII, AFLP2/VNIV and AFLP1/VNI), only the cross of AFLP6/VGII × AFLP2/VNIV exhibited mating response. Hybridization between the two cryptococcal species complexes seems to be a much rarer event in nature compared to hybridization between *C*. *neoformans* species complex lineages\[[@pntd.0008493.ref042]\]. Even though the mating between the parental lineages can be induced in the laboratory, their progenies were not commonly reported in the environmental and clinical samples\[[@pntd.0008493.ref043]\]. Recombination may also occur between the AFLP4/VGI and AFLP6/VGII isolates in China because previous research has highlighted possible gene transfer (introgression) between different *C*. *gattii s*.*l*. clades, either bisexually or unisexually, thereby contributing to the production of virulence subtypes\[[@pntd.0008493.ref041], [@pntd.0008493.ref044]\]. Sex can contribute to *de novo* diversity\[[@pntd.0008493.ref045]\], which may be the reason for the diversity in the MLST analysis of clinical *C*. *deuterogattii* isolates. In addition, the capacity for mating could generate additional infectious propagules, leading to increased exposure and, ultimately, an enhanced infection rate\[[@pntd.0008493.ref031]\].

Clinical data from this study showed that almost all patients had no obvious immunodeficiency, except one patient with SLE, which was consistent with the fact that the *C*. *gattii* species complex causes infection in immunocompetent hosts\[[@pntd.0008493.ref011]\]. Most strains in Guangxi, southern China had the capabilities to produce melanin and capsule, as well as to undergo sexual reproduction. These are major virulence factors known to contribute to *Cryptococcus* pathogenesis and have been well characterized in *C*. *gattii* species complex. However, very few past studies have investigated these virulence factors in Chinese strains. Our data showed that most Chinese strains, similar to the reference outbreak strain R265 from Canada, have the abilities to be virulent. However, animal model studies need to be performed in order to establish their virulence levels to human hosts and whether their virulence would be comparable to the highly virulent outbreak (R265) and less virulent strain (R272) from the PNW\[[@pntd.0008493.ref029]\].

Most patients significantly relieved after combination therapy while one patient (GX0147) passed away after giving up treatment because of no significant improvement. However, antifungal susceptibility testing indicated that strains in this study are not resistant to antifungal drugs because their MIC values were within the susceptible range\[[@pntd.0008493.ref033]--[@pntd.0008493.ref035]\]. Therefore, although none of the strains demonstrated resistance to these drugs, other factors may complicate the therapeutic outcomes of these patients.

*Cryptococcus* can be dispersed through the movement of trees and wood products, air currents, water currents, and biotic sources, such as birds, animals and insects\[[@pntd.0008493.ref013]\]. Unlike *C*. *neoformans* species complex, which is found commonly in soils contaminated with wild and pet bird droppings, especially pigeon droppings, *C*. *gattii* species complex prefer to grow within and underneath moist bark, tree hollows, tree trunks and in soil debris near specific trees that are often found in nature (including *Eucalyptus*, *Azadirachta*, *Castanopsis*, *Prunus dulcis*, *Pinus canariensis* and *Pseudotsuga menziesii*)\[[@pntd.0008493.ref046]\]. The evidence for *C*. *gattii* species complex dispersal by wind and air currents is limited, but fungal isolations from air samples have been obtained around positive trees in Canada and India\[[@pntd.0008493.ref013]\]. "Guangxi Autonomous Region" belongs to southern China and lays on the southeastern corner of the Yunnan-Guizhou Plateau, situated from 20º54′N to 26º24′N and from 104º26′E to 112º04′E. This region borders Vietnam to the southwest and is surrounded by Guangdong, Guizhou, Yunnan, and Hunan Provinces in China. The region has a terraced topography sloping from the northwest to the southeast, with hilly land constituting 85% of its total area and plains constituting 15%. The region has a subtropical humid monsoon climate, with average daily temperatures of 16°C to 23°C. The rainy season lasts from April until September, with an annual rainfall of 1500 mm to 2000 mm\[[@pntd.0008493.ref047]\]. The warm, subtropical monsoon climate in Guangxi is also favorable for the growth and reproduction of the *C*. *gattii* species complex. In this study, most patients were farmers in rural areas and had a history of contact with above plants and soil, especially *Eucalyptus*, but without travel record to the epidemic areas such as the PNW region, or the endemic area of *C*. *gattii* species complex such as South America and Australia, indicating that their cryptococcosis infection was spread through contact with the local environment. Frequent and regular contact with the natural environment may explain how these patients acquired the infections\[[@pntd.0008493.ref048]\]. The genetic variabilities of Chinese *C*. *gattii* species complex members also suggested the possibility of multiple independent origins. Combined with the phylogenetic analysis of this study, some Chinese strains were related to those from Brazil. Therefore, this may be traced to the wood/seedlings imported from elsewhere, such as South America and Australia\[[@pntd.0008493.ref049]\]. However, additional isolation and investigation of the *C*. *gattii* species complex from the environment such as trees, soil and wild animals is necessary to establish the environment as the source of infection in Guangxi Province, China.

Cryptococcosis infections caused by the *C*. *gattii* species complex are relatively rare in comparison to those caused by the *C*. *neoformans* species complex (11.4% versus 88.6%)\[[@pntd.0008493.ref015]\]; however, recent studies have indicated that they may be mis- or underdiagnosed globally\[[@pntd.0008493.ref050]\]. Similarly, the number of *C*. *gattii* species complex infections in China may be underestimated. Compared with the data from other provinces in China\[[@pntd.0008493.ref014], [@pntd.0008493.ref051]\], the rate of *C*. *gattii* species complex infection in Guangxi was approximately 9% (11/120), and most infection were caused by *C*. *deuterogattii*; however, additional epidemiological and surveillance studies are required.

There are several limitations of this study. First, a small number of patients were included in the study. Second, due to the retrospective nature of study, there was no long-term follow-up assessment of these patients, which have led to some missing data. Third, the level of virulence among these strains still needs further study on animal models. Fourth, environmental isolates should be sampled to assess the relationship of environmental niche for *C*. *gattii* species complex in this area. Thus, performing a prospective study with a larger study population are expected to elucidate the population structure and mechanisms of *C*. *gattii* species complex. Presently, we are in collaboration with other hospitals to carry out regional surveillance of *Cryptococcus* infections in China.

In summary, the *C*. *gattii* species complex should receive substantial attention in China due to its genetic variability, ability to infect immunocompetent hosts and propensity to undergo sexual reproduction and cause outbreaks, even the number of infections was low. Given that all patients in this investigation may have acquired the infection from nature, the environmental distribution, genetic variability and virulence level of the *C*. *gattii* species complex should not be underestimated. At the same time, we strive to improve the differential diagnosis of the *C*. *gattii* species complex in the early stages of infection and to use targeted treatment programs to reduce the risk of infection.

Supporting information {#sec017}
======================

###### Genetic relationships of *C*. *gattii s*.*s*.

\(a\) and *C*. *deuterogattii* (b) between Guangxi, southern China, and global isolates illustrated by principal component analysis (PCA).

(PDF)
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Click here for additional data file.

###### 

(a)Visual analysis of melanin production after fungal growth on caffeic acid agar at 30°C and 37°C for three days. (b) Polysaccharide capsule surrounding the cells of *C. deuterogattii* isolates under microscopy. (c) Capsule production test in RPMI-1640 with 5% CO~2~ at 37°C representing the average capsule-capsule:cell wall-cell wall ratio of the six clinical isolates and the reference strain (AFLP6A/VGIIa R265). (X400, *p* \< 0.001) (error bars ± SE = 2 SE).

(PDF)

###### 

Click here for additional data file.
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Editor: 120 clinical isolates are mentioned as the "population" from which these 11 strains were drawn. Were all consecutive cryptococcal isolates (cultured from patients at First Affiliated Hospital of Guangxi Medical University) stored for study purposes between 2014-2018? If not, please specify this. Provide information on the clinical source (specimen type) and patient characteristics for all 120 isolates, if this is possible. What does "the outer court treatment" in Table 1 refer to? Please summarise the main limitations of this study in the discussion section.

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: The objectives are clear with the appropriate design. The screening of 120 clinical strains between 2014-2018 by L-concanavanine-glycine-bromthymol blue (CGB) medium showed 11 Cryptococcus gattii species complex from Non-HIV patients in South China. Five of C. gattii ss (and six of C. deuterogattii (AFLP6A/VGIIa) Mating and susceptibility test against 7 common antifungal agents were investigated. The genetic variation and phylogenetic tree using MLST information were analyzed fertility

However:

1\. The first sentence of materials and methods: 120 clinical strains were collected\...\.... It is not clear whether 120 clinical strains of which group of organisms they recruited for CGB screening.

2\. The demography, association diseases, antifungal agents profiles, genetic variation, and phylogenetic trees were analyzed based on 11 isolates after screening of 120 isolates (might be suspected Cryptococcus spp.??).

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: - Table 1: \-- More detail of clinical syndrome and temp. of fever should be mentioned to let the readers learn from experience of the authors and any other laboratory diagnosis was examined or not, ie: cryptococcal antigen.

\-- Environment contact : Eucalyptus and pigeon. Actually Cryptococcus\'s habitat is not only the Eucalyptus and pigeon. It can be the tree bark, the hollow of big trees and other avian exclude from pigeon. Thus, isn\'t it leads the readers to misunderstand the environment niche.

\- Genetic variation and phylogenetic trees based on the 7 loci-MSLT performing were analyzed and the result showed the association with the global isolates.

\- Fertility was detected. Capsule sIze and melanin pigment formation were all comparable to standard strains.

\- The 7 antifungal agents profiles against these 11 C. gattii cpx according to the CLSI protocol were investigated.

\- The antifungal drug dosage and duration of treatment are other significance factors to let the readers get some information for the survivals and decease.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: This authors concluded that the mating α C. gattii complex were isolated from clinical specimens in South China between 2014-2018 and all these emerging 11 isolates, (10%, if 120 isolates were Cryptococcus spp.) are all susceptible to antifungal agents. The small genetic variation, 8STs, in their isolates were found and related to the reported strains from other countries. The distribution of C. gattii cpx. in this area might due to the capability of sexual reproduction. The authors proposed the future study to confirm the virulence in animal model.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: Minor revision: - as mentioned above regarding more clinical symptom, antifungal dosage,

\- the original group in the CGB screening, more explanation about the environment niche, not only Eucalyptus tree,..

\- Clinical manifestation and/or diagnosis should provide more information, ie: GX0717 chest pain and specimens : Lung tissue. This information does not provide any more info. It is just like common things. How the X-ray? How is

\- The best condition for Laccase gene: melanin pigment formation will be 30C is already the theory so I donot think this will give any benefit for this experiment.

-The limitation of sample should be focused in discussion.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: Dear Editor

The manuscript entitled "Emerging Cryptococcus gattii species complex infection in south China" by Huang et al, presented the link between C. deuterogattii isolates from south China and those from Brazil, Spain, Singapore, USA and France. Although the number of isolates in this study was quite small (N=11), this report would trigger some interesting points for further investigation to see how C. gattii complex spreads worldwide. There are some comments for the manuscript.

1\. For the mating experiment, why the authors performed the experiment using JEC20 to mate with C. gattii complex. The JEC20 is C. neoformans serotype D, not C. gattii complex. The authors should use C. gattii complex MATa to do the experiment to make it more convincing. In the discussion Line 318-322, the authors mentioned that sexual reproduction could cause genetic diversity from these results. Is it usual that C. gattii mate with C. neoformans in the environment?

2\. The capsule and melanin production in these virulent strains is not unexpected as those virulent factors are well-known. Therefore, these data did not add anything new. To make it more convincing, the capsule and melanin experiments need a non-virulent (environmental) C. gattii strain as a negative control (in addition to R265 strain). In this case, R272 (environmental C. gattii isolate) may be used as a control to show that it produces less capsule and melanin that the China isolates.

3\. Line284 "......our data revealed no significant different (p \< 0.01) in ....". This is confusing why it was not significant as the p value was \< 0.01.

4\. The authors should discuss why they use triple drug combination to treat C. gattii infection (amphotericin B plus fluconazole plus flucytosine). Is there any guideline in China recommend this combination therapy?

Reviewer \#2: (No Response)

Reviewer \#3: The authors tried to provide the emerging information of C. gattii complex in 2014-2018 in South China and demonstrated how significant they are thru the virulence factors, mating, capsule formation, melanin formation. In addition, the genetic variation of their strains are associate with the global strains which imply that this is not the result from recombination inside South China.
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If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Data Requirements:
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Dear Pro. cao,

We are pleased to inform you that your manuscript \'Emerging Cryptococcus gattii species complex infection in Guangxi, southern China\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.
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IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.
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Todd B. Reynolds
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Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: The content in materials and methods are corresponded to the listed questions except the grammar of the verb after the data shouldn\'t be \"were\" not was (L173). The authors revised and provided the clear image of how the isolates derived from and how to proof the isolates which the experiments used the standard methods. Multilocus sequencing typing (MLST), one of the standard and verified tool to analyse the new sequence types were performed . However, the authors should provide the full name before write the short name (L.196). The ethical concern was clarified.

\*\*\*\*\*\*\*\*\*\*

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: The authors edited the results as comments, making the clear results. Each issue was clarified and finally the authors could show the new STs and characterised Cryptococcus gattii in Guangxi, southern China and showed how these eleven isolates related to Cryptococcus in other locations. Their antifungal profiles and demography of patients were laborated.

\*\*\*\*\*\*\*\*\*\*

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: The summary and the limitations were explained.
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**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: Two points were already pointed out: grammatical error and the full name.
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**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: Dear editor,

The authors have explained clearly in the \"response to reviewers\" and the revised manuscript. The data they presented would interest the readers. I have no further question.

Regards,
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Dear Pro. cao,
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Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.
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